Top View
- WO 2013/068875 Al 16 May 2013 (16.05.2013) P O P C T
- The Endothelium As a Target for Anti-Atherogenic Therapy:A
- Lipid Management- for Prevention of Cardiovascular Events: Editor Ronnie Aronson Recent Trials and New Approaches MD, FRCPC, FACE
- PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2016) Annotated for Statistical Reporting Purposes
- New Therapeutic Developments in Lipidology
- Measurement of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in the Assessment of Cardiovascular Risk
- Therapeutic Modulation of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)
- Effect Modification of Interventions
- Developing Medicines That Mimic the Natural Successes of the Human Genome Lessons from NPC1L1, HMGCR, PCSK9, APOC3, and CETP*
- Pharmaabkommen A1 E
- Imaging As a Surrogate Marker of Drug Efficacy in Cardiovascular Disease
- (12) United States Patent (10) Patent No.: US 8,048,880 B2 Trias Et Al
- Indole Derivative Indolderivat Dérivé D’Indole
- Cardiovascular Toolkit
- Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events
- Measurement of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in the Assessment of Cardiovascular Risk
- Utility of Biomarkers and Imaging in the Development of Drugs for the Treatment of Coronary Atherosclerosis David D
- The Beneficial Effects of the Lab4 Probiotic Consortium in Atherosclerosis
- Tribulations of Recent Cardiology Trials, the Audacity of Hope, and HOPE-3 David D
- 1 List of Ongoing Research Studies at Medanta
- Human-Like Atherosclerosis in Minipigs: a New Model for Detection
- Different Approaches in Therapy Aiming to Stabilize an Unstable Atherosclerotic Plaque
- Aps2011127.Pdf
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Enzyme Inhibitors Enzymes Are Biological Catalysts That Drive Various Reactions Within a Cell
- Darapladib for Cardiovascular Risk Reduction in Patients with Coronary Heart Disease – Add on Therapy
- FUTURE TREATMENTS the Future of Treatment Options for Dyslipidemia Will Most Likely Involve the Evaluation of Other Parameters Besides LDL-C
- Measurement of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in the Assessment of Cardiovascular Risk